Join leading experts at the 2025 Inflammatory Skin Disease Summit to explore groundbreaking research and innovations in dermatologic care and therapies.
Emma Guttman-Yassky, MD, PhD
Advertisement
As the chair of the department of dermatology at the Icahn School of Medicine at Mount Sinai in New York City, Emma Guttman-Yassky, MD, PhD, and her team see roughly two thirds of dermatology patients in the city of New York and has become 1 of the 3 largest departments in the United States.
Articles by Emma Guttman-Yassky, MD, PhD
A late-breaking EADV presentation revealed that ritlecitinib significantly improved outcomes in patients with multiple forms of scarring alopecia.
The biologic’s less frequent injections could ease logistical and emotional strain for patients with atopic dermatitis and their families.
By targeting IL-13, APG777 may allow for less frequent dosing compared to existing biologics.
At EADV 2025, she showcased how OX40 and JAK inhibition offer complementary approaches to long-term disease control.
Discover promising advancements in vitiligo treatments, including innovative therapies and combination approaches that enhance skin repigmentation and improve patient quality of life.
Many patients with severe AD are unaware of newer, more effective treatments.
Advertisement
Latest Updated Articles
Ritlecitinib Shows Early Efficacy in Alopecia SubtypesPublished: October 9th 2025 | Updated:
APG777 May Ease Burden on Patients With ADPublished: October 7th 2025 | Updated:
How Emerging Therapies Are Changing the AD Treatment LandscapePublished: February 8th 2025 | Updated:
Guttman-Yassky Discusses APG777 as a Potential Breakthrough in ADPublished: September 24th 2025 | Updated:
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Reviewing Type 2 Inflammation Through a Different Lens
3
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
